US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
AAPL
$333.69
▲+1.02%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
AAPL
$333.69
▲+1.02%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Relief Therapeutics Hldg
(OP:
RLFTF
)
0.2655
UNCHANGED
Last Price
Updated: 2:52 PM EDT, Aug 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Relief Therapeutics Hldg
< Previous
1
2
3
4
5
6
7
Next >
Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU
July 13, 2022
Company acquires an additional therapeutic product for the management of patients with PKU for worldwide markets, with the exception of the United Kingdom, thereby complementing and enhancing its...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
July 04, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / July 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), announced today that it has filed Amendment No. 4 to its Registration...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Regulatory Compliance
Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk
July 04, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / July 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
↗
July 01, 2022
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.
Via
Benzinga
FDA Rejects Acer Therapeutics - Relief Therapeutics' Urea Cycle Disorder Candidate
↗
June 21, 2022
Via
Benzinga
Relief Therapeutics Files Amendment No. 3 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
June 17, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / June 17, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), announced today that it has filed Amendment No. 3 to its Registration...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Regulatory Compliance
Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil
June 13, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / June 13, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports that its Collaboration Partner, Acer Therapeutics, Issued a Statement Regarding the PDUFA Target Action Date for ACER-001
June 08, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / June 8, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
↗
June 05, 2022
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended.
Via
Benzinga
Relief Therapeutics Announces Results of Annual General Meeting of RELIEF THERAPEUTICS Holding SA
June 01, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / June 1, 2022 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (" Relief " or the " Company "), a biopharmaceutical company seeking to provide patients...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
↗
May 31, 2022
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,...
Via
Benzinga
Relief Provides a Corporate Update and Comments on the Recently Announced DSMB Update on the U.S. National Institutes of Health (NIH) Study of Intravenous Aviptadil in Critical COVID-19 Patients
May 31, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / May 31, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19
May 26, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / May 26, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF), (OTCQB:RLFTF, RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Expands U.S. Commercial Team
May 23, 2022
Tracy Truong and Kelli Powell Appointed Regional Clinical Specialists for the West and Northeast Regions, RespectivelySeasoned Account Managers Bring Extensive Pharmaceutical Sales Experience in Rare...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
May 11, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / May 11, 2022 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (" Relief "), announced today that it has filed Amendment No. 2 to its Registration...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Regulatory Compliance
Relief Therapeutics to Participate in Industry and Investor Conferences in May
May 09, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / May 9, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
May 06, 2022
NEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / May 6, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY)...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA
May 06, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / May 6, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTY) ("Relief" or the "Company"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R)
April 27, 2022
Notice of Allowance of Patent Application for Modified Release Orally Administered Amino Acid Formulations, Strengthens Proprietary Position in U.S. until 2036 GENEVA, SWITZERLAND / ACCESSWIRE / April...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Relief Therapeutics Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing
April 26, 2022
Proven Pharmaceutical Marketing Leader Brings Extensive Experience in Rare Diseases, Digital Innovation and New Product Launches to Relief's U.S. Commercial Team GENEVA, SWITZERLAND / ACCESSWIRE /...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil
April 22, 2022
Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil in a Subgroup of Patients with Critical COVID-19 with Respiratory Failure that...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
April 12, 2022
NEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / April 12, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Reports Execution of Stipulation with NeuroRx and Jonathan Javitt to Continue Mediation Process
April 05, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / April 5, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), today reported that it has entered into a stipulation to stay the...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
April 01, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / April 1, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19
April 01, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / April 1, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports Full-Year 2021 Results and Provides Corporate Update
March 31, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / March 31, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Reports In Vivo Data Indicating Prolonged Release of Amino Acids Using its Physiomimic(TM) Technology May Have Benefits for the Treatment of PKU
March 28, 2022
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports In Vivo Data Published in the Peer Reviewed, International Journal of Molecular Sciences, Indicating Prolonged Release...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Receives Trademark Registration for RLF-100(R) From the U.S. Patent and Trademark Office
March 24, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / March 24, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Relief Therapeutics Appoints Christopher Wick as Senior Director, Head of U.S. Sales
March 21, 2022
Proven Pharmaceutical Sales Professional Brings Big Pharma Experience to Relief's U.S. Expansion Activities GENEVA, SWITZERLAND / ACCESSWIRE / March 21, 2022 / RELIEF THERAPEUTICS Holding SA (SIX: RLF,...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
March 21, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / March 21, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY)("Relief"), announced today that it has filed Amendment No. 1 to its Registration...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Regulatory Compliance
< Previous
1
2
3
4
5
6
7
Next >
